923 related articles for article (PubMed ID: 25797698)
1. Epigenomes as therapeutic targets.
Hamm CA; Costa FF
Pharmacol Ther; 2015 Jul; 151():72-86. PubMed ID: 25797698
[TBL] [Abstract][Full Text] [Related]
2. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy--a new development in pharmacology.
Peedicayil J
Indian J Med Res; 2006 Jan; 123(1):17-24. PubMed ID: 16567863
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
Vendetti FP; Rudin CM
Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
8. Targeting epigenetic DNA and histone modifications to treat kidney disease.
Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Treatment Options in Urothelial Carcinoma.
Pinkerneil M; Hoffmann MJ; Niegisch G
Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
[TBL] [Abstract][Full Text] [Related]
11. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
13. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
14. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
16. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases.
Vincent A; Ducourouble MP; Van Seuningen I
FASEB J; 2008 Aug; 22(8):3035-45. PubMed ID: 18492726
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
20. A new paradigm in toxicology and teratology: altering gene activity in the absence of DNA sequence variation.
Reamon-Buettner SM; Borlak J
Reprod Toxicol; 2007 Jul; 24(1):20-30. PubMed ID: 17596910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
